Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

MediStem and Superview to Develop Antibodies that Affect Stem Cells

publication date: Oct 1, 2012
MediStem of San Diego formed a stem cell collaboration with Superview Biotechnology Co., a subsidiary of Yinhuan Holding. The two companies will use MediStem’s proprietary stem cell lines to screen monoclonal antibodies. Their goal will be to assess whether antibodies can modulate the activity of stem cells that already exist in the body. The companies will evaluate various candidates jointly, as well as apply for grants and share research data. More details....

Stock Symbol: (Pink Sheets: MEDS)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital